...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
Due Dilligence
Annual General Meeting Presentation 6/22/2021
See also imtesty's rough transcript here: https://agoracom.com/ir/Resverlogix/forums/discussion/topics/762730-reposting-with-link-included/messages/2320824#message
Posted by:
BearDownAZ
on
Jun 23, 2021 09:13AM
May 12, 2021: PBA à Noon Presentation with Resverlogix Corp.
See also imtesty's rough transcript here: https://agoracom.com/ir/Resverlogix/forums/discussion/topics/760671-rough-transcript-rvx-21-05-12-pba-at-noon/messages/2315891#message
Posted by:
BearDownAZ
on
May 18, 2021 10:42AM
Resverlogix Corp. Links
New Share Price Contest update to midnight Oct 30th 2019
Posted by:
BearDownAZ
on
Oct 31, 2019 08:52AM
SfN 2019 Poster - Apabetalone Epigenetically Inhibits Monocyte Adhesion to Brain Endothelial Cells by Downregulating Key Neuroinflammation Markers In Vitro and In Vivo
Posted by:
BearDownAZ
on
Oct 25, 2019 08:54AM
Seeking Alpha: Resverlogix To Release Phase 3 Clinical Trial Data On A First-In-Class BET Bromodomain Inhibitor
Posted by:
BearDownAZ
on
Sep 25, 2019 09:54AM
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease
Posted by:
BearDownAZ
on
Sep 21, 2019 09:20PM
Apabetalone Modulates Th1 Responses in Diabetes and CVD Through Intrinsic and Extrinsic Mechanisms: in vitro and in human study - EASD 2019 Poster
Posted by:
BearDownAZ
on
Sep 17, 2019 09:58AM
Epigenetics in CVD: A collection of PACE-CME symposium presentations Link #1
Posted by:
BearDownAZ
on
Sep 04, 2019 12:47PM
BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE Trial - ESC 2019 Poster
Posted by:
BearDownAZ
on
Sep 04, 2019 12:35PM
Apabetalone (RVX-208) Inhibits Key Drivers of Vascular Inflammation, Calcification, and Plaque Vulnerability Through a BET-dependent Epigenetic Mechanism - ESC 2019 Poster
Posted by:
BearDownAZ
on
Sep 04, 2019 12:34PM